Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Gains from Investment Securities (2016 - 2025)

Angiodynamics (ANGO) has disclosed Gains from Investment Securities for 16 consecutive years, with -$593000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 29750.0% year-over-year to -$593000.0, compared with a TTM value of -$530000.0 through Nov 2025, down 402.86%, and an annual FY2024 reading of $432000.0, down 81.38% over the prior year.
  • Gains from Investment Securities was -$593000.0 for Q4 2025 at Angiodynamics, down from $91000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.0 million in Q2 2023 and bottomed at -$593000.0 in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $180842.1, with a median of $32000.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities skyrocketed 2075.0% in 2022, then tumbled 29750.0% in 2025.
  • Year by year, Gains from Investment Securities stood at $32000.0 in 2021, then crashed by 625.0% to -$168000.0 in 2022, then soared by 176.79% to $129000.0 in 2023, then tumbled by 98.45% to $2000.0 in 2024, then crashed by 29750.0% to -$593000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for ANGO at -$593000.0 in Q4 2025, $91000.0 in Q3 2025, and -$30000.0 in Q1 2025.